1. Home
  2. Live Updates
  3. Revised international staging system

Live Breaking News & Updates on Revised international staging system

Stay informed with the latest breaking news from Revised international staging system on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Revised international staging system and stay connected to the pulse of your community

FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma

The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.

Bristol-myers-squibb , Bryan-campbell , International-staging-system , Cell-therapy , Eligibility-criteria , Revised-international-staging-system , Multiple-myeloma , Ide-cel , Cart-cell-therapy , Abecma ,

Belantamab Mafodotin Plus Vd More Than Doubles PFS in Relapsed/Refractory Multiple Myeloma

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma.

United-states , Roche-genentech , Rachid-baz , Abbvie-genentech , International-staging-system , Amgen , Moffitt-cancer-center , Glaxosmithkline , Pfizer , Revised-international-staging-system , Belantamab-mafodotin , Multiple-myeloma

Idecabtagene Vicleucel Approaches EU Approval in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

The EMA's CHMP has recommended the approval of idecabtagene vicleucel in patients with multiple myeloma who received at least 2 prior therapies.

Anne-kerber , International-staging-system , Oncologic-drugs-advisory-committee , Late-clinical-development , European-commission , Bristol-myers-squibb , European-medicines-agency , Medicinal-products , Human-use , Cell-therapy , Revised-international-staging-system , Drugs-advisory-committee

New Multiple Myeloma Staging Systems Outperform the Standard

Findings from a large US cohort study show comparable accuracy, but better discrimination of patients across disease stages.

United-states , Salt-lake-city , Utah , University-of-utah , American , Manni-mohyuddin , Flatiron-health , Huntsman-cancer-institute , American-society-of-hematology , International-staging-system , American-society , Revised-international-staging-system

Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023

Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San-diego , California , United-states , Shanghai , China , Suzhou , Jiangsu , American , Wendy-li , Exchange-commission , American-society-of-hematology , Fierce-life-sciences-innovation

Gracell Biotechnologies Presents Updated Clinical Data From Fastcar-T GC012F Demonstrating Deep And Durable Responses In Newly Diagnosed Multiple Myel...

Gracell Biotechnologies Presents Updated Clinical Data From Fastcar-T GC012F Demonstrating Deep And Durable Responses In Newly Diagnosed Multiple Myel...
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

San-diego , California , United-states , Shanghai , China , Suzhou , Jiangsu , American , Wendy-li , Fierce-life-sciences-innovation , Gracell-biotechnologies-inc , American-society-of-hematology

Isa-KRd Significantly Improves MRD Negativity Rates at Cutoffs Vs KRd in Newly Diagnosed Multiple Myeloma

The combination of Isa-KRd significantly increased the rates of minimal residual disease negativity at cutoffs post-consolidation vs KRd in patients with newly diagnosed multiple myeloma.

Italy , Azienda-ospedaliero-universitaria-citt , University-of-torino , Health-sciences , Second-revision-of-international-staging-system , Department-of-molecular-biotechnology , International-staging-system , International-myeloma-working-group , Molecular-biotechnology , Second-revision , Revised-international-staging-system , Isa-krd

Dr Midha on Real-World Data With Teclistamab in Relapsed/Refractory Multiple Myeloma

Shonali Midha, MD, discusses real-world data with teclistamab in patients with relapsed/refractory multiple myeloma.

Shonali-midha , Harvard-medical-school , International-staging-system , Dana-farber-cancer-institute , Dana-farber-cancer , Revised-international-staging-system ,

Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate

Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented at the International Myeloma Society Annual Meeting 100% ...

Athens , Attikír , Greece , United-states , China , Shanghai , Suzhou , Jiangsu , American , Wendy-li , Nasdaq , International-myeloma-society

Earlier Use of Ide-Cel May Increase Benefit for Patients With High-Risk R/R Myeloma

Krina K. Patel, MD, MSc, expands on the importance of evaluating outcomes for treatment with ide-cel in patients with relapsed/refractory multiple myeloma with different high-risk characteristics and key findings from the high-risk subgroup analysis of the KarMMa-3 trial.

Houston , Texas , United-states , Krinak-patel , International-staging-system , Pfizer , Curio-sciences , University-of-texas-md-anderson-cancer-center , Department-of-lymphoma-myeloma , Bristol-myers-squibb , Astrazeneca